Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma

Table 1 Tumor characteristics according to level of Tsuv_max/Lsuv_mean

	Tsuvmax/Lsuvmean	Tsuvmax/Lsuvmean	P value
	< 1.90 (n = 43)	≥1.90 (n = 40)
Mean age ± SD (yr)	60 ± 11.7	59.9 ± 9.7	0.276
Sex (male:female)	34:9	34:6	0.574
Etiology			0.802
HBV/HCV/alcohol/others	35/4/1/3	34/5/0/1
Tumor number	1.8 ± 1.3	2.7 ± 1.8	0.008
Single/multiple			0.008
Tumor size (cm)	5.2 ± 3.2	10 ± 5.5	0.000
< 3 cm	14	1	0.000
3-5 cm	11	8
> 5 cm	18	31
Portal vein thrombosis			0.000
Absent/present	39/4	18/22
Child-Pugh class			0.758
A/B	36/7	35/5
Serum AFP (ng/dL)	2928.5 ± 11573.6	35275.2 ± 103428	0.011
< 400/> 400	30/13	18/22	0.028
BCLC stage			0.000
A/B/C	21/13/9	7/28/2005

HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Serum α-fetoprotein; BCLC: Barcelona clinic liver cancer score.

Table 2 Tumor characteristics according to objective response

	Objective response group(n = 45)	Non-objective response group(n = 38)	P value
Mean age ± SD (yr)	60.8 ± 11.5	59.0 ± 9.7	0.372
Sex (male:female)	37:8	31:7	0.940
Etiology			0.555
HBV/HCV/alcohol/others	36/5/1/3	33/4/0/1
Tumor number			0.077
Single/multiple	25/20	13/25
Tumor size (cm)	4.4 ± 2.3	11.2 ± 4.9	0.000
Portal vein thrombosis			0.000
Absent/present	42/3	15/23
Child-Pugh class			0.756
A/B	38/7	33/5
Serum AFP	3795 ± 12054	35951 ± 106137	0.054
BCLC stage			0.000
A/B/C	26/12/7	0/8/30
Tsuvmax/Lsuvmea			0.000
1.90 </≥ 1.90	34/11	9/29

HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Serum α-fetoprotein; BCLC: Barcelona clinic liver cancer score.

Table 3 Univariate and multivariate analysis for the factors that influence objective response

	P value
Factors	Univariate	Multivariate
Tumor number single/multiple	0.077	0.357
Tumor size (cm)	0.000	0.530
Portal vein thrombosis	0.000	0.386
Absent/present
BCLC stage	0.000	0.408
A/B/C
Tsuvmax/Lsuvmean	0.000	0.020
1.90 </≥ 1.90

BCLC: Barcelona clinic liver cancer score.

Table 4 Analysis of treatment response according to standardized uptake value ratio by barcelona clinic liver cancer score staging

		Treatment response
BCLC stage	Tsuvmax/Lsuvmean	CR	PR	SD	PD	Total	P value
A	< 1.90	18	3	0	0	21	1.0
(n = 26)	≥ 1.90	4	1	0	0	5
B	< 1.90	5	3	2	3	13	0.048
(n = 20)	≥ 1.90	0	4	3	0	7
C	< 1.90	2	4	4	0	10	0.000
(n = 37)	≥ 1.90	0	1	11	15	27
Total		29	16	20	18	83

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; BCLC: Barcelona clinic liver cancer score.

Table 5 Multivariate analysis for the factors that influence overall survival rates

Factors	P value	Exp (B)	95% CI
Age
< 60 yr/≥ 60 yr	0.135	0.814	0.832-3.955
Tumor size
< 3 cm	0.520
3-5 cm	0.456	2.420	0.269-20.861
> 5 cm	0.519	0.689	0.237-2.320
Tumor number
Single/multiple	0.079	0.413	0.154-1.107
Portal vein thrombosis
Absent/present	0.348	0.636	0.247-1.638
BCLC stage
A	0.032
B	0.034	0.082	0.008-0.824
C	0.053	0.314	0.097-1.017
Tsuvmax/Lsuvmean
1.90 </≥ 1.90	0.036	0.337	0.122-0.932

BCLC: Barcelona clinic liver cancer score; CI: Confidence interval.